S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
OTCMKTS:NEVPF

Abliva AB (publ) (NEVPF) Stock Price, News & Analysis

$0.01
0.00 (0.00%)
(As of 04/18/2024 ET)
Today's Range
$0.01
$0.01
50-Day Range
$0.01
$0.02
52-Week Range
$0.01
$0.02
Volume
N/A
Average Volume
N/A
Market Capitalization
$4.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NEVPF stock logo

About Abliva AB (publ) Stock (OTCMKTS:NEVPF)

Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

NEVPF Stock Price History

NEVPF Stock News Headlines

Probi AB
IVSXF Investor AB (publ)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Interfox Resources publ AB (IFOX)
Cell Impact publ AB (CELLI)
Abliva AB (publ) (NEVPF)
See More Headlines
Receive NEVPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abliva AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:NEVPF
CIK
N/A
Employees
8
Year Founded
N/A

Profitability

Net Income
$-8,450,000.00
Pretax Margin
-6,314,897.50%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.04 per share

Miscellaneous

Free Float
N/A
Market Cap
$4.03 million
Optionable
Not Optionable
Beta
N/A
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Ellen K. Donnelly Ph.D. (Age 50)
    Chief Executive Officer
    Comp: $4.97M
  • Ms. Catharina Jz Johansson (Age 57)
    Deputy CEO, CFO & VP of Investor Relations
  • Dr. Eskil Elmér M.D. (Age 54)
    Ph.D., Chief Scientific Officer & VP of Discovery
    Comp: $247k
  • Daniel Schale
    Director of Communications
  • Dr. Magnus Hansson (Age 48)
    Chief Medical Officer and VP of Preclinical & Clinical Development
  • Mr. Dag Nesse
    Vice President of Clinical Operations
  • Dr. Lars Vedin
    Consultant

NEVPF Stock Analysis - Frequently Asked Questions

How have NEVPF shares performed in 2024?

Abliva AB (publ)'s stock was trading at $0.01 at the start of the year. Since then, NEVPF stock has increased by 0.0% and is now trading at $0.01.
View the best growth stocks for 2024 here
.

How do I buy shares of Abliva AB (publ)?

Shares of NEVPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:NEVPF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners